Corcept Therapeutics (CORT) Cash from Operations (2010 - 2026)

Corcept Therapeutics has disclosed Cash from Operations across 17 years of filings, most recently posting 16772000.0 for Q1 2026.

• Cash from Operations for Q1 2026 came in at 16772000.0, down 451.61% year-over-year; the trailing twelve-month figure through Mar 2026 was 120454000.0 (down 32.82% YoY), and the FY2025 annual result was 141996000.0, down 28.39% from the prior year.
• Cash from Operations came in at 16772000.0 for Q1 2026 at Corcept Therapeutics, down from 38448000.0 in the prior quarter.
• In the past five years, Cash from Operations ranged from a high of 73293000.0 in Q3 2024 to a low of 16772000.0 in Q1 2026.
• The 5-year median for Cash from Operations is 35247000.0 (2022), against an average of 33560176.47.
• Across the five-year window, Cash from Operations soared 986.24% in 2024 and plunged 451.61% in 2026, its largest moves.
• Corcept Therapeutics' Cash from Operations stood at 33388000.0 in 2022, then slumped by 83.44% to 5529000.0 in 2023, then jumped by 986.24% to 60058000.0 in 2024, then plunged by 35.98% to 38448000.0 in 2025, then tumbled by 143.62% to 16772000.0 in 2026.
• The last three Cash from Operations figures came in at 16772000.0 (Q1 2026), 38448000.0 (Q4 2025), and 54481000.0 (Q3 2025), per Business Quant data.